Michael W. DeGregorio Department of Internal Medicine, Division of Hematology and Oncology University of California, Davis Biography Publications Institution JoVE Articles Michael W. DeGregorio has not added a biography. If you are Michael W. DeGregorio and would like to personalize this page please email our Author Liaison for assistance. Publications Ospemifene for the Treatment of Dyspareunia Associated with Vulvar and Vaginal Atrophy: Potential Benefits in Bone and Breast International Journal of Women's Health. 2013 | Pubmed ID: 24109197 Antitumor Effects of L-BLP25 Antigen-Specific Tumor Immunotherapy in a Novel Human MUC1 Transgenic Lung Cancer Mouse Model Journal of Translational Medicine. Mar, 2013 | Pubmed ID: 23496860 Ospemifene, Vulvovaginal Atrophy, and Breast Cancer Maturitas. Jan, 2013 | Pubmed ID: 23332519 Ospemifene and 4-hydroxyospemifene Effectively Prevent and Treat Breast Cancer in the MTag.Tg Transgenic Mouse Model Menopause (New York, N.Y.). Jan, 2012 | Pubmed ID: 21926925 Pharmacologic Evaluation of Ospemifene Expert Opinion on Drug Metabolism & Toxicology. Jun, 2010 | Pubmed ID: 20429673 Pharmacologic Effects of Ospemifene in Rhesus Macaques: a Pilot Study Basic & Clinical Pharmacology & Toxicology. Jun, 2008 | Pubmed ID: 18346046 Ineffectiveness of American Ginseng in the Prevention of Dimethylbenzanthracene-induced Mammary Tumors in Mice Oncology Research. 2006 | Pubmed ID: 17476970 Selective Estrogen Receptor Modulators Inhibit Growth and Progression of Premalignant Lesions in a Mouse Model of Ductal Carcinoma in Situ Breast Cancer Research : BCR. 2005 | Pubmed ID: 16280035 Ospemifene Inhibits the Growth of Dimethylbenzanthracene-induced Mammary Tumors in Sencar Mice The Journal of Steroid Biochemistry and Molecular Biology. Nov, 2005 | Pubmed ID: 16153821 Effects of Ospemifene and Raloxifene on Hormonal Status, Lipids, Genital Tract, and Tolerability in Postmenopausal Women Menopause (New York, N.Y.). Mar, 2005 | Pubmed ID: 15772568 Pharmacokinetics of Selective Estrogen Receptor Modulators Clinical Pharmacokinetics. 2003 | Pubmed ID: 12648026 SERMs: Current Status and Future Trends Critical Reviews in Oncology/hematology. Jul, 2002 | Pubmed ID: 12098608 Induktion af Invasive Transitional Cell blærecarcinom i Immune intakt humant MUC1 transgene mus: En model for immunterapi Development Daniel P. Vang1, Gregory T. Wurz1, Stephen M. Griffey2, Chiao-Jung Kao1, Audrey M. Gutierrez1, Gregory K. Hanson1, Michael Wolf3, Michael W. DeGregorio1 1Department of Internal Medicine, Division of Hematology and Oncology, University of California, Davis, 2Comparative Pathology Laboratory, UC Davis School of Veterinary Medicine, University of California, Davis, 3Merck Serono Research, Merck KGaA, Darmstadt, Germany JoVE 50868 Medicine
Induktion af Invasive Transitional Cell blærecarcinom i Immune intakt humant MUC1 transgene mus: En model for immunterapi Development Daniel P. Vang1, Gregory T. Wurz1, Stephen M. Griffey2, Chiao-Jung Kao1, Audrey M. Gutierrez1, Gregory K. Hanson1, Michael Wolf3, Michael W. DeGregorio1 1Department of Internal Medicine, Division of Hematology and Oncology, University of California, Davis, 2Comparative Pathology Laboratory, UC Davis School of Veterinary Medicine, University of California, Davis, 3Merck Serono Research, Merck KGaA, Darmstadt, Germany JoVE 50868 Medicine
